Skip NavigationSkip to Content

Causal and putative pathogenic mutations identified in 39% of children with primary steroid-resistant nephrotic syndrome in South Africa

  1. Author:
    Nandlal, Louansha
    Winkler, Cheryl A
    Bhimma, Rajendra
    Cho, Sungkweon
    Nelson,George
    Haripershad, Sudesh
    Naicker, Thajasvarie
  2. Author Address

    Discipline of Optics and Imaging, University of KwaZulu-Natal, Durban, South Africa. loun0406@gmail.com., Basic Research Program, Molecular Genetics Epidemiology Section, Frederick National Laboratory of the National Cancer Institute, Washington, DC, USA., Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa., Frederick National Laboratory for Cancer Research, Frederick Advanced Biomedical Computational Science, Washington, DC, USA., Department of Nephrology, University of KwaZulu-Natal, Durban, South Africa.,
    1. Year: 2022
    2. Date: Aug 03
    3. Epub Date: 2022 08 03
  1. Journal: European Journal of Pediatrics
  2. Type of Article: Article
  1. Abstract:

    There is a paucity of data identifying genetic mutations that account for the high rate of steroid-resistant nephrotic syndrome (SRNS) in a South African paediatric population. The aim was to identify causal mutations in genes implicated in SRNS within a South African paediatric population. We enrolled 118 children with primary nephrotic syndrome (NS), 70 SRNS and 48 steroid-sensitive NS. All children with SRNS underwent kidney biopsy. We first genotyped the NPHS2 gene for the p.V260E variant in all NS cases (n?=?118) and controls (n?=?219). To further identify additional variants, we performed whole-exome sequencing and interrogated ten genes (NPHS1, NPHS2, WT1, LAMB2, ACTN4, TRPC6, INF2, CD2AP, PLCE1, MYO1E) implicated in SRNS with histopathological features of focal segmental glomerulosclerosis (FSGS) in 56 SRNS cases and 29 controls; we also performed exome sequencing on two patients carrying the NPHS2 p.V260E mutation as positive controls. The overall detection rate of causal and putative pathogenic mutations in children with SRNS was 27/70 (39%): 15 (21%) carried the NPHS2 p.V260E causal mutation in the homozygous state, and 12 (17%) SRNS cases carried a putative pathogenic mutation in the heterozygous state in genes (INF2 (n?=?8), CD2AP (n?=?3) and TRPC6 (n?=?1)) known to have autosomal dominant inheritance mode. NPHS2 p.V260E homozygosity was specifically associated with biopsy-proven FSGS, accounting for 24% of children of Black ethnicity (15 of 63) with steroid-resistant FSGS. No causal or putative pathogenic mutations were identified in NPHS1, WT1, LAMB2, PLCE1, MYO1E and ACTN4. We report four novel variants in INF2, PLCE1, ACTN4 and TRPC6.   Conclusion: We report putative missense variants predicted to be pathogenic in INF2, CD2AP and TRPC6 among steroid-resistant-FSGS children. However, the NPHS2 p.V260E mutation is a prevalent cause of steroid-resistant FSGS among Black South African children occurring in 24% of children with SRNS. Screening all Black African children presenting with NS for NPHS2 p.V260E will provide a precision diagnosis of steroid-resistant FSGS and inform clinical management. What is Known: • Limited data is available on the genetic disparity of SNRS in a South African paediatric setting. • The high rate of steroid resistance in Black South African children with FSGS compared to other racial groups is partially explained by the founder variant NPHS2 p.V260E. What is New: • We report putative missense variants predicted to be pathogenic in INF2, CD2AP and TRPC6 among steroid-resistant FSGS children. • NPHS2 p.V260E mutation remains a prevalent cause of steroid-resistant FSGS among Black South African children, demonstrating precision diagnostic utility. © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

    See More

External Sources

  1. DOI: 10.1007/s00431-022-04581-x
  2. PMID: 35920919
  3. PII : 10.1007/s00431-022-04581-x

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel